Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.56 |
| ▸ | CA1 | P00915 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | CA9 | Q16790 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10013657 | 0.98 | CA12 (0.55) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL4283848 | 0.82 | ALDH1A1 (0.81) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL5822282 | 0.82 | CA12 (0.58) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL13661591 | 0.82 | MAPT (0.70) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL3852333 | 0.81 | KMT2A (0.58) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL18629170 | 0.81 | CA12 (0.56) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL84849 | 0.81 | ALDH1A1 (0.57) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL25803770 | 0.81 | CA12 (0.56) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL11028517 | 0.80 | CA12 (0.56) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL3893911 | 0.79 | CA12 (0.63) | CA12CA1CA2CA9NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180162867-A1 | EIS INHIBITORS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162867-A1 | EIS INHIBITORS | EP300, ACAT1, ACAT2 | CA12 4483/4885CA1 4516/4885CA2 4312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.